Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$3.57
+1.1%		$3.59
$2.60
▼
$14.68
$30.71M1.1608,853 shs108,238 shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$65.16
-4.2%		$74.50
$39.70
▼
$123.75
$661.98M-5.36131,627 shs93,010 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.63
+5.5%		$3.33
$2.77
▼
$7.18
$1.84B1.0714.58 million shs29.01 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
+1.13%-4.29%+2.00%+15.91%-56.73%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-4.20%-10.51%-18.55%-5.57%+50.59%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+5.52%+8.68%+14.51%+9.34%-21.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$3.57
+1.1%		$3.59
$2.60
▼
$14.68
$30.71M1.1608,853 shs108,238 shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$65.16
-4.2%		$74.50
$39.70
▼
$123.75
$661.98M-5.36131,627 shs93,010 shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$3.63
+5.5%		$3.33
$2.77
▼
$7.18
$1.84B1.0714.58 million shs29.01 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
+1.13%-4.29%+2.00%+15.91%-56.73%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-4.20%-10.51%-18.55%-5.57%+50.59%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+5.52%+8.68%+14.51%+9.34%-21.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
1.00
SellN/AN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3.00
Buy$143.83120.74% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.06122.04% Upside

Current Analyst Ratings Breakdown

Latest BCTX, DRUG, and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeMarket Perform
8/20/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/19/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$145.00
8/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.30
8/17/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$147.00
7/21/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2026
Briacell Therap stock logo
BCTX
Briacell Therap
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A$9.20 per shareN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$22.84 per shareN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M26.02N/AN/A$1.71 per share2.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$26.31M-$7.92N/AN/AN/AN/A-153.53%-129.26%N/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$8.74M-$2.08N/AN/AN/AN/A-12.46%-12.30%N/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)

Latest BCTX, DRUG, and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/17/2026Q3 2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$1.2230-$0.17+$1.0530-$0.17N/AN/A
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
6/9/2026Q3 2026
Briacell Therap stock logo
BCTX
Briacell Therap
N/A-$0.99N/A-$0.99N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
7.07
7.07
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
122.00
122.00
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03

Institutional Ownership

CompanyInstitutional Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
15.42%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%

Insider Ownership

CompanyInsider Ownership
Briacell Therap stock logo
BCTX
Briacell Therap
0.74%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
42.66%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
88.70 million8.64 millionNo Data
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A9.73 million5.58 millionNot Optionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400535.34 million499.74 millionOptionable

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.9% Higher - Here's What Happened
September 4 at 1:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-trading-69-higher-heres-what-happened-2026-09-04/
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
September 4 at 12:37 PM  |  zacks.comhttps://www.zacks.com/stock/news/2985293/why-is-recursion-pharmaceuticals-rxrx-up-8-2-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2985293
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
September 3 at 11:35 AM  |  zacks.comhttps://www.zacks.com/stock/news/2984455/can-rxrx-s-pipeline-expansion-strengthen-its-long-term-growth-outlook?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2984455
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 30,000 Shares
September 3 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rxrx-insider-buying-and-selling-2026-09-03/
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 30,000 Shares of Stock
September 2 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-recursion-pharmaceuticals-nasdaq-rxrx-director-blake-borgeson-sells-30000-shares-of-stock-2026-09-02/
Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded at Wall Street Zen
August 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989292
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Sell at Wall Street Zen
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-recursion-pharmaceuticals-nasdaq-rxrx-rating-increased-to-sell-at-wall-street-zen-2026-08-29/
Recursion Pharmaceuticals, Inc. (RXRX)
August 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RXRX/earnings-calls/
Stock Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-stock-traders-purchase-high-volume-of-recursion-pharmaceuticals-call-options-nasdaq-rxrx-2026-08-26/
Bank of America Corp DE Buys 384,486 Shares of Recursion Pharmaceuticals, Inc. $RXRX
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-384486-shares-of-recursion-pharmaceuticals-inc-rxrx-2026-08-26/
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.3% - Here's What Happened
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-recursion-pharmaceuticals-nasdaq-rxrx-stock-price-up-63-heres-what-happened-2026-08-25/
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 7% - Here's What Happened
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-trading-down-7-heres-what-happened-2026-08-24/
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of "Hold" by Analysts
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-inc-nasdaqrxrx-given-average-rating-of-hold-by-analysts-2026-08-24/
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.8% - Still a Buy?
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-nasdaqrxrx-shares-up-98-still-a-buy-2026-08-19/
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zacks-analyst-blog-highlights-recursion-074300158.html
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/contineum-disc-medicine-recursion-advance-150138340.html
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
August 17, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975676/4-ai-powered-drug-discovery-stocks-to-watch-as-ai-reshapes-pharma?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2975676
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/recursion-pharmaceuticals-highlights-ai-platform-roche-progress-and-pipeline-updates-2026-08-17/
Recursion (RXRX) Q2 2026 Earnings Call Transcript
August 12, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/12/recursion-rxrx-q2-2026-earnings-call-transcript/
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934810-recursion-pharmaceuticals-inc-rxrx-presents-at-bank-of-america-smid-cap-virtual-conference
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX)
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/stock-traders-purchase-high-volume-of-put-options-on-recursion-pharmaceuticals-nasdaqrxrx-2026-08-11/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Cardinal Health branded boxes on pallets sit amid automated conveyor systems in a distribution warehouse.
Cardinal Health Earnings: Can Perfection Get Priced In Twice?
By Chris Markoch | August 12, 2026
Eli Lilly logo displayed among medicine vials, pill bottles, blister packs, and injector pens on a table.
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
By Chris Markoch | September 2, 2026
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
By Chris Markoch | September 4, 2026
Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$3.57 +0.04 (+1.13%)
As of 09/4/2026 04:00 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$65.16 -2.86 (-4.20%)
As of 09/4/2026 04:00 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$3.63 +0.19 (+5.52%)
As of 09/4/2026 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas